What options are there to do a genetical analysis of my tumor?What are the potential benefits, risk and trade offs....

According to NCCN Guidelines for Anal Carcinoma (2023):

OVERVIEW:

1. Pre-treatment Testing:

• Molecular testing is recommended particularly for HPV-negative cases as they often have different molecular profiles
• Key biomarkers include: PD-L1, MSI/MMR status, and tumor mutational burden (TMB)

1. Post-treatment Testing:

• Additional molecular profiling may be valuable if there's disease progression after standard therapy
• Can help identify potential targeted therapy options or clinical trial eligibility

RECOMMENDED TESTING (per ASCO Guidelines):

1. Essential Tests:

• MSI/MMR status
• PD-L1 expression
• Comprehensive genomic profiling

Main Testing Companies & Coverage:

1. Foundation Medicine Pros:

• FDA-approved comprehensive testing
• Widely accepted by insurance including Cigna
• Extensive panel covering 324+ genes Cons:
• Longer turnaround time (2-3 weeks)
• May require prior authorization

1. Caris Life Sciences Pros:

• Comprehensive molecular profiling
• Good insurance coverage
• Includes RNA sequencing Cons:
• More expensive if not covered
• Variable turnaround times

1. Tempus Pros:

• Fast turnaround time
• AI-powered analysis
• Good for rare cancers Cons:
• More limited insurance coverage
• Newer to market

According to the National Cancer Institute's recommendations:

TIMING CONSIDERATIONS: Pre-treatment:

• Helps guide initial therapy decisions
• May identify clinical trial opportunities
• More tissue typically available

Post-treatment:

• Can guide second-line therapy
• May identify resistance mechanisms
• Limited by tissue availability

Summary Table:

Test Type | Pre-treatment | Post-treatment ---|---|--- MSI/MMR | Essential | Recommended PD-L1 | Essential | Recommended Comprehensive Genomic Profiling | Recommended | Essential Targeted Panel | Optional | Recommended

RECOMMENDATIONS:

1. For your specific case (HPV-negative SCCA):

• Comprehensive molecular profiling is strongly recommended due to HPV-negative status
• Foundation Medicine's FDA-approved test would be the primary recommendation due to:
  • Cigna coverage
  • Comprehensive analysis
  • Established track record

1. Testing Timeline:

• If pre-treatment: Proceed before starting therapy if possible
• If post-treatment: Consider testing if:
  • Disease progression occurs
  • Clinical trial options are being considered

Always discuss with your oncology team as they can:

• Coordinate testing
• Handle insurance authorization
• Interpret results in context of your specific case

Sources:

1. NCCN Guidelines for Anal Carcinoma (2023)
2. ASCO Molecular Testing Guidelines (2022)
3. National Cancer Institute Biomarker Testing Guidelines

Remember: This information is meant to inform discussions with your healthcare team, who can provide personalized recommendations based on your specific clinical situation.